Durvalumab vs Sitagliptin

## Durvalumab vs Sitagliptin: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Sitagliptin**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Sitagliptin**: DPP-4 inhibitor increasing incretin levels.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Sitagliptin — 12.4 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Sitagliptin — C16H15F6N5O.

**Molecular Weight**: Durvalumab — N/A; Sitagliptin — 407.3140 g/mol.

**Type**: Durvalumab — Antibody; Sitagliptin — Small molecule.